Last updated: July 18, 2026
GE Healthcare Limited v. Jubilant DraxImage Inc. (2:24-cv-06486): Litigation Summary, Patent Issues, and Risk Outlook
GE Healthcare Limited is suing Jubilant DraxImage Inc. in the US District Court for the District of New Jersey (case no. 2:24-cv-06486). The docket caption indicates a patent infringement action, but the specific patents asserted, claims at issue, infringement theories, and requested relief are not provided in the information available here. Without the asserted patent list and the operative complaint or schedule, a complete, accurate litigation summary cannot be produced.
What patents are asserted in GE Healthcare v. Jubilant DraxImage (2:24-cv-06486)?
A litigation summary requires the asserted patent numbers (and ideally, the claim map framing). The case number alone does not identify the patent estate or the particular technology at issue.
Which patent numbers and assignees matter?
No asserted patent identifiers are available in the provided information, so the patent numbers, assignees, and expiration profiles cannot be enumerated.
What claim categories are typically disputed?
A complete response depends on the complaint’s structure (independent and dependent claims, product vs method claims, and any additional asserted patents). Those details are not available here.
What is the procedural posture in 2:24-cv-06486 (complaint, motions, schedules)?
A procedural posture analysis depends on docket events: complaint filing date, service completion, responsive pleadings, Rule 12 motions, claim construction (if any), preliminary injunction motions, discovery schedule, and trial setting.
No docket event details are provided, so the litigation stage cannot be determined.
Has there been a Rule 12 motion or transfer/venue dispute?
No information is provided on motions to dismiss, venue challenges, or amendments.
Are there any Markman proceedings or claim construction orders?
No claim construction or scheduling orders are provided.
What does GE Healthcare allege Jubilant infringes? (product, process, method-of-use)
In patent cases, the infringement theory is determined by the asserted claims and the allegation paragraphs tied to specific products or manufacturing steps. Without the complaint text or the infringement allegations, the infringement scope cannot be stated accurately.
Are product claims or manufacturing method claims at issue?
Not available from the provided data.
Is the case tied to FDA regulatory submissions?
If the case involves radiopharmaceuticals, imaging agents, or related manufacturing, litigation often intersects with 505(b)(2), ANDAs, or Section 351(k) pathways, but no regulatory linkage is provided here.
When does exclusivity expire and how does that affect the litigation strategy?
Exclusivity timelines depend on the underlying patents (utility, formulation, method-of-use), and any regulatory exclusivity tied to the drug or imaging agent. The case number does not provide those anchors.
What are the patent expiration dates and terminal disclaimers?
Not available.
What regulatory exclusivity could constrain generic entry risk?
Not available.
How strong is GE Healthcare’s patent estate versus Jubilant’s design-around options?
A strength assessment requires claim scope, prosecution history, prior art citations, and infringement plausibility based on the accused product structure or process. None of that is included in the provided information.
What prior art or obviousness risks exist?
Not available.
What design-around pathways are suggested by claim language?
Not available.
Are there Paragraph IV or 351(k)-type themes in this case?
For Hatch-Waxman and 351(k) parallel litigation, the record often includes certifications, Orange Book patents, and a tie to an ANDA or biosimilar applicant. No such items are included here.
Is there an FDA listing overlap (Orange Book patents)?
Not available.
Has Jubilant made any generic/biosimilar certifications?
Not available.
How does similar litigation involving GE Healthcare usually play out in federal court?
A comparative pattern analysis requires at least one of: (i) asserted patents, (ii) same product/technology family, or (iii) prior related case numbers. None are available.
What remedies are typically sought (injunctions, damages, attorneys’ fees)?
Not available for this case.
What settlement signals exist for 2:24-cv-06486 (consent, dismissal, stay, consent judgment)?
Settlement or ADR indicators typically appear in docket events (stipulations, joint motion to stay, mediation order, or dismissal without prejudice). No docket events are provided.
Has the court ordered mediation or a stay pending PTAB?
Not available.
Is there an agreed launch/date carve-out?
Not available.
Key Takeaways
- The case caption confirms GE Healthcare Limited is suing Jubilant DraxImage Inc. in 2:24-cv-06486.
- A litigation summary that is specific and decision-grade requires the asserted patent numbers and operative allegations/scheduling events.
- Those essential inputs are not present in the provided information, so a complete and accurate summary cannot be generated.
FAQs
- What court and judge are assigned in GE Healthcare Limited v. Jubilant DraxImage Inc. (2:24-cv-06486)?
- Which specific patents does GE Healthcare assert in 2:24-cv-06486?
- What is the current procedural stage for 2:24-cv-06486 and what deadlines control discovery?
- Does the complaint tie the infringement allegations to an FDA submission by Jubilant DraxImage?
- What settlement posture or consent-docket events exist in 2:24-cv-06486?
References
- United States District Court, District of New Jersey, GE Healthcare Limited v. Jubilant DraxImage Inc., Case No. 2:24-cv-06486 (docket information).
